HKPD Company Profile and Key Details

HKPD has shown mixed momentum, losing -0.04% over the past week and -32.31% over the past quarter, though year-to-date performance is down -3.12%. Short-term trend indicators are bullishly aligned (SMA20 -14.39%, SMA50 -16.25%, SMA200 -42.95%). The stock’s 14-day RSI is 31.55 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.45% below its high and over 3.13% above its low. Average 10-day trading volume of 14.01 million shares is significantly above the 3-month average of 2.27 million, indicating heightened recent market interest.

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) closed at $0.18 USD, losing -$0.15 (-45.54%) from the previous close of $0.33. The stock is currently mid-range between its 52-week high and low $0.15 and $1.82. With a market capitalization of about $1.99 million, Cellyan Biotechnology Co., Ltd is classified as a micro-cap and shows higher-than-market volatility (beta ~2.33). Key stats such as the average daily volume over the past year has been around 747.70 thousand shares, trading with heavier-than-usual volume. Headquartered in Hong Kong, None, Cellyan Biotechnology Co., Ltd operates in the Healthcare sector and the Medical - Distribution industry. Led by CEO Chenyu Liang, the company employs approximately 27 people and listed since January 15, 2025. Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China.

Cellyan Biotechnology Co., Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

Cellyan Biotechnology Co., Ltd has 41.35 million shares outstanding. The public float is 15.71 million shares, elevated short interest at 6.35% of float. This equals 467.46 thousand shares. The short ratio is 0.36 days. Institutional investors hold 0.47% of the float. Insiders own 33.13%.

Cellyan Biotechnology Co., Ltd trades at a P/E ratio of -9.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.17 and a price-to-book ratio of 0.76 suggesting the stock is closer to book value. The P/FCF stands at -2.84, also below market averages.

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) shares are flat -3.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cellyan Biotechnology Co., Ltd trading at a premium to the broader market with a P/E of -9.33. Our AI forecast model points to short-term strength (37.74% over two weeks), a medium-term rise (21.21% over three months), and a longer-term loss (-28.37% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cellyan Biotechnology Co., Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 37.74%, with price expected at $0.25 by September 15, 2026, within a range of $0.21 to $0.29 3-Month Outlook: Projected rise of 21.21%, reaching $0.22 by November 27, 2026, with a range of $0.16 to $0.27. 1-Year Outlook: Projected loss of -28.37%, with price at $0.13 by September 01, 2027, within a range of $0.09 to $0.16.